Health facilities are being set up now in Liberia to take blood serum from Ebola survivors for transfusions in the treatment of infected patients. Facilities in Sierra Leone and Guinea will soon follow. WHO also announced the French government is ready to begin in Guinea clinical trials of a Japanese-developed Ebola vaccine called Favipiravi. Known as T-705, it is marketed by Toyama Chemical under the trade name Avigan. WHO also announced human Phase 1 clinical trials of two experimental Ebola vaccines are expected to begin by the end of October or the beginning of November. WHO is ready to test on humans the two frontrunner experimental vaccines it approved in a conference in Geneva Sept....
↧